Ātma
/from ancient sanskrit:आत्मा
inner essence, breath or soul
ATMA was intentionally founded with the goal to support healthcare professionals looking to integrate psychedelic medicine into their practices.
There is a growing body of evidence demonstrating the efficacy of psychedelic compounds and new applications are constantly being studied. Needless to say, here at ATMA, we are committed to advancing this field.
Our mission
Our team brings forth a diverse set of skills that allows us to analyze and refine what is necessary for the psychedelic industry to efficiently and ethically increase accessibility to these remarkable medicines. To execute these goals, we’ve cultivated strong relationships with industry-leading experts, mental healthcare professionals, and Health Canada.
Our vision
The one thing our team has in common is a passion for this field and for developing innovative solutions for the challenges that the psychedelic industry faces. We envision a world where individuals do not have to struggle for access to these life-changing medicines.

Why choose ATMA?
ATMA designs training programs, systems, networks, and infrastructure to support healthcare professionals in preparation for legalization of psychedelic-assisted therapy. In alignment with our mission, ATMA provides a clear, guided path for clinics and healthcare professionals to practicably adopt psychedelic-assisted therapy into their current practices.
The road to adoption is not without its challenges for healthcare professionals; ATMA aims to reduce this steep learning curve and to provide solutions to such challenges.
Challenges | Our Solutions |
---|---|
Knowledge - Insufficient practical education and training programs for therapy providers. | Providing practical and applicable education and training programs; the only program to provide experiential participation in open clinical trials. |
Operational – Ad hoc efforts to provide psychedelic-assisted services is not feasible for traditional clinics and therapy providers. | Developing a technology platform that streamlines the practice of psychedelic therapy, thus increasing practicality and cost effectiveness. |
Clinical Time – Therapy providers already struggle with managing their current workloads. | Creating a network of support services will allow therapy providers more time to focus on the provision of therapy. |
Resources – There are no current initiatives to build support systems and infrastructure to assist clinics and therapy providers. | Building a full turn-key system solution and infrastructure to support clinics and therapy providers in providing psychedelic-assisted therapy. |
Who is ATMA for?
- Healthcare professionals who wish to acquire practical education and training, with the intent to offer psychedelic-assisted therapy and or consultation to clients.
- Healthcare professionals wanting ongoing support in providing psychedelic-assisted therapy upon legalization.
- Healthcare professionals who wish to belong to and contribute to building a strong psychedelic practitioner community.
Meet our team
Medical Advisory Board

Dr. Ravinder Bains
Chief Medical Officer

Lyle Galloway
Consultant

Bruce Sanguin
Consultant
Executive and Advisory Team

David Harder
Founder, Co-CEO and Board Member

Vu Tran
Founder, Co-CEO and Board Member

Murray Rodgers
Executive Advisor and Board Member

Brad Giblin
Chief Financial Officer

Natalie Harder
Vice President,
Programming
Administrative and Clinical Team

Tabetha White
Office and Intake
Coordinator

Debbie White
Intake Coordinator

Chad Plante
Intake Coordinator

Kandice Wirch
Palliative Care Program Coordinator

Jenni Bennett
Medical Writer

Genie Nguyen
Digital Media
Coordinator
Interested in joining our team?
We’re always looking to add compassionate, experienced and committed professionals to our team as we expand our services and reach.
No current listings available.